Related Experiment Videos
Nonclinical pharmacologic and toxicologic considerations for evaluating biologic products
1Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland 20857.
Regulatory Toxicology and Pharmacology : RTP
|December 1, 1989
Summary
Developing biologic products requires tailored preclinical studies for each unique compound, moving beyond generic protocols. This approach ensures safety and efficacy from initial human trials through later-stage clinical evaluations.
Area of Science:
- Biologics Development
- Pharmacology and Toxicology
- Regulatory Science
Background:
- Biologic products necessitate preclinical evaluation for safety and efficacy before human trials.
- Generic preclinical protocols are insufficient due to the unique nature of each biologic.
- Regulatory agencies like the FDA require tailored approaches for biologic drug development.
Purpose of the Study:
- To outline the FDA's thought process for addressing nonclinical pharmacology and toxicology concerns for biologics.
- To provide a framework for developing tailored preclinical study designs for diverse biologic products.
- To share insights based on historical data for initiating Phase 1 and progressing to Phase 2/3 clinical studies.
Main Methods:
- Analysis of past preclinical and clinical development pathways for various biologic products.
- Review of Food and Drug Administration (FDA) considerations for nonclinical pharmacology and toxicology.
- Case-by-case assessment of unique biologic compounds, including peptide hormones, cytokines, vaccines, and monoclonal antibodies.
Main Results:
- Established that unique toxicologic concerns and study designs are essential for each biologic product.
- Demonstrated the inadequacy of generic preclinical protocols for the diverse range of biologics.
- Highlighted the importance of tailored approaches for regulatory approval and clinical progression.
Conclusions:
- Preclinical pharmacology and toxicology studies must be customized to the specific biologic product.
- A flexible, compound-specific strategy is crucial for successful biologic drug development and regulatory review.
- This approach supports the safe and effective progression of biologics from preclinical research to human clinical trials.